Form 4 for WST West Pharmaceutical Services
Accepted 2024-05-09 00:00:00 ET · period of report 2024-05-07 · accession 0001127602-24-014765 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-09 | 2024-05-07 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | M - OptEx | $58.89 | +75.0K | 218.9K | +52% | +$4.42M |
| DM | 2024-05-09 | 2024-05-07 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | S - Sale+OE | $366.65 | -66.0K | 210.0K | -24% | -$24.20M |
| DM | 2024-05-09 | 2024-05-07 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | M - OptEx | $0.00 | -75.0K | 36.7K | -67% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-07 | M | A | 9,316 | $57.38 | 162,224.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 2 | Common | Common Stock | 2024-05-07 | M | A | 9,000 | $59.64 | 161,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 3 | Common | Common Stock | 2024-05-07 | S | D | 41,000 | $366.65 | 152,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. (F2) The price reported in Column 4 is a weighted average price. |
| 4 | Common | Common Stock | 2024-05-07 | S | D | 15,684 | $366.66 | 193,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. (F2) The price reported in Column 4 is a weighted average price. |
| 5 | Common | Common Stock | 2024-05-07 | M | A | 15,684 | $57.38 | 177,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 6 | Common | Common Stock | 2024-05-07 | M | A | 41,000 | $59.64 | 218,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 7 | Common | Common Stock | 2024-05-07 | S | D | 9,316 | $366.64 | 209,952.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. (F2) The price reported in Column 4 is a weighted average price. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-05-07 | M | D | 41,000 | $0.00 | 45,732 | D | $59.64 · 2017-02-23 to 2026-02-23 | 41,000 Common Stock | |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-05-07 | M | D | 15,684 | $0.00 | 0 | D | $57.38 · 2016-02-23 to 2025-04-24 | 15,684 Common Stock | |
| 10 | Derivative | Stock Option (Right to Buy) | 2024-05-07 | M | D | 9,316 | $0.00 | 0 | D | $57.38 · 2015-04-24 to 2025-04-24 | 9,316 Common Stock | |
| 11 | Derivative | Stock Option (Right to Buy) | 2024-05-07 | M | D | 9,000 | $0.00 | 36,732 | D | $59.64 · 2017-02-23 to 2026-02-23 | 9,000 Common Stock |